These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 16135831

  • 21. [Paget's disease of bone].
    Holgado Pérez S, Sallés Lizarzáburu M, Olivé Marqués A.
    Med Clin (Barc); 2008 Oct 18; 131(13):509-12. PubMed ID: 19007581
    [No Abstract] [Full Text] [Related]

  • 22. [Paget's disease: case report].
    Wegierska M, Ignaczak P, Zalewska J, Jeka S.
    Ann Acad Med Stetin; 2011 Oct 18; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [Abstract] [Full Text] [Related]

  • 23. [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects].
    Kapczuk K, Sowińska-Przepiera E, Friebe Z.
    Ginekol Pol; 2003 Apr 18; 74(4):323-31. PubMed ID: 12916277
    [Abstract] [Full Text] [Related]

  • 24. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ.
    Cancer; 2003 Feb 01; 97(3 Suppl):887-92. PubMed ID: 12548591
    [Abstract] [Full Text] [Related]

  • 25. RANKing the importance of measles virus in Paget's disease.
    Ross FP.
    J Clin Invest; 2000 Mar 01; 105(5):555-8. PubMed ID: 10712423
    [No Abstract] [Full Text] [Related]

  • 26. Prediction and assessment of the response of Paget's disease to bisphosphonate treatment.
    Hosking DJ.
    Bone; 1999 May 01; 24(5 Suppl):69S-71S. PubMed ID: 10321933
    [Abstract] [Full Text] [Related]

  • 27. [Treatment of Paget's disease of bone with zoledronic acid].
    Body JJ, Sternon J.
    Rev Med Brux; 2005 May 01; 26(6):513-7. PubMed ID: 16454155
    [Abstract] [Full Text] [Related]

  • 28. Paradoxical acute hypercalcemic effect of salmon calcitonin in patients having Paget's disease of bone after treatment with dichloromethylene diphosphonate.
    Delmas PD, Chapuy MC, Meunier PJ.
    Horm Metab Res; 1984 May 01; 16(5):258-61. PubMed ID: 6234216
    [Abstract] [Full Text] [Related]

  • 29. Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.
    Reid IR, Sharma S, Kalluru R, Eagleton C.
    Calcif Tissue Int; 2016 Sep 01; 99(3):322-5. PubMed ID: 27193832
    [Abstract] [Full Text] [Related]

  • 30. Determinants of remission of Paget's disease of bone.
    Patel S, Stone MD, Coupland C, Hosking DJ.
    J Bone Miner Res; 1993 Dec 01; 8(12):1467-73. PubMed ID: 8304048
    [Abstract] [Full Text] [Related]

  • 31. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan 01; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 32. Updates on Paget's Disease of Bone.
    Choi YJ, Sohn YB, Chung YS.
    Endocrinol Metab (Seoul); 2022 Oct 01; 37(5):732-743. PubMed ID: 36327984
    [Abstract] [Full Text] [Related]

  • 33. Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools.
    Heymann D, Fortun Y, Rédini F, Padrines M.
    Drug Discov Today; 2005 Feb 15; 10(4):242-7. PubMed ID: 15708742
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Osteoclast diseases.
    Helfrich MH.
    Microsc Res Tech; 2003 Aug 15; 61(6):514-32. PubMed ID: 12879419
    [Abstract] [Full Text] [Related]

  • 40. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin.
    Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Türk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G.
    Arthritis Rheum; 2002 Mar 15; 46(3):785-92. PubMed ID: 11920416
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.